Peter Cancelmo Sells 25,000 Shares of Omeros (NASDAQ:OMER) Stock

Omeros Corporation (NASDAQ:OMER) VP Peter Cancelmo sold 25,000 shares of the business’s stock in a transaction on Monday, August 31st. The shares were sold at an average price of $18.54, for a total value of $463,500.00. Following the sale, the vice president owned 200 shares in the company, valued at approximately $3,708. The trade was a 99.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Omeros Stock Performance

Shares of OMER opened at $18.86 on Thursday. Omeros Corporation has a 52-week low of $3.94 and a 52-week high of $19.65. The stock’s 50-day simple moving average is $13.14 and its 200 day simple moving average is $12.19. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of 14.73 and a beta of 2.60.

Omeros (NASDAQ:OMER) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The company had revenue of $28.53 million for the quarter, compared to analysts’ expectations of $12.69 million. On average, research analysts forecast that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Omeros

A number of institutional investors have recently made changes to their positions in OMER. State of Wyoming bought a new stake in shares of Omeros during the 4th quarter worth $25,000. B. Riley Wealth Advisors Inc. bought a new position in Omeros in the second quarter valued at $32,000. Caitong International Asset Management Co. Ltd bought a new position in Omeros in the fourth quarter valued at $33,000. Assetmark Inc. purchased a new stake in Omeros during the first quarter valued at about $38,000. Finally, Tower Research Capital LLC TRC lifted its stake in Omeros by 829.6% during the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 11,971 shares during the last quarter. Institutional investors own 48.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on OMER shares. Wall Street Zen raised shares of Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Weiss Ratings upgraded shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. HC Wainwright reaffirmed a “buy” rating on shares of Omeros in a report on Monday, July 27th. Finally, Zacks Research downgraded Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Omeros has a consensus rating of “Moderate Buy” and an average target price of $38.00.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.